PTPN2 and myeloid sarcoma: miR-448 is significantly increased in both PBMCs and cerebrospinal fluid of patients with MS and enhances the production of pro-inflammatory cytokines, including IL-1β and IL-17, through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2) thus promoting Th17 differentiation (37).